This report highlights the key discussions and insights from the APACMed CEO Delegation’s 2026 Beijing Conference, exploring China’s evolving role as a global MedTech innovation hub and the growing opportunities for international collaboration. Supported by government policies, expanding R&D capabilities, and a strong innovation ecosystem, China is transitioning from a major manufacturing base and commercial market into an increasingly important source of globally relevant medical technologies.
Drawing on perspectives from policymakers, industry leaders, and healthcare experts, the report examines three key areas: cooperation between Chinese and multinational MedTech companies, AI-driven digital transformation, and clinical-needs-driven innovation. It explores opportunities for cross-border partnerships while addressing challenges in regulatory alignment, clinical adoption, data governance, reimbursement, and international commercialization.
The report also reviews China’s accelerating MedTech development, the overseas expansion of Chinese companies, and emerging partnership models that combine local innovation with global expertise. It concludes with recommendations for APACMed to strengthen industry collaboration, facilitate policy dialogue, and support the adoption and commercialization of innovative medical technologies across the Asia-Pacific region.